Business Context and Reporting Period
This Form 8-K filing by Vanda Pharmaceuticals Inc. reports on executive compensation decisions made by the Compensation Committee on February 27, 2019. The report covers the award of 2018 annual bonuses and the approval of 2019 base salaries, bonus targets, and equity grants for named executive officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation figures:
- 2018 Bonuses Awarded: Total cash bonuses for the five named executive officers ranged from $71,918 to $700,000, with one award denominated in Swiss Francs (CHF 274,500).
- 2019 Base Salaries: Approved annual base salaries range from $386,250 to $721,000 (with one officer's salary in CHF 502,640).
- 2019 Bonus Targets: Target bonus percentages range from 40% to 80% of the respective 2019 base salary.
- Equity Grants: Options were granted with an exercise price of $20.62 per share. Total options granted to the five officers sum to 420,000 shares, and total RSUs granted sum to 180,000 shares.
Material Changes
The filing does not report material changes to the company's financial position, operations, or market conditions compared to prior periods. It details the standard annual compensation cycle adjustments and new equity grants.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, outlook, or discussion of risks and contingencies. Management commentary is limited to the statement that the Compensation Committee reviewed an analysis of executive compensation compared to a peer group conducted by Willis Towers Watson prior to making these awards.
Investor Verification Checklist
- Verify the total dilution impact of the 420,000 new stock options and 180,000 RSUs granted.
- Confirm the exchange rate used to convert the CHF-denominated compensation for the Chief Commercial Officer into USD for financial reporting.
- Review the vesting schedules: Options vest monthly over four years; RSUs vest annually over four years starting March 1, 2020.
- Assess the alignment of the 2018 bonus amounts with the company's actual performance metrics for the year ended December 31, 2018.